A star scientist in the world of single-cell genomics and computational biology is leaving academia to become one of the few women leading R&D at a biotech company.
Aviv Regev, a core institute member of the Broad Institute of MIT and Harvard, will become head of Genentech research and early development effective Aug. 1, its parent company, Roche (RHBBY), announced Monday. She will join the Swiss biopharma company’s corporate executive committee and report to Roche CEO Severin Schwan.
“Why have I decided to make this change? Like many of you, I am driven by two factors: an innate curiosity for how our cells and bodies work, and a desire to turn that knowledge into something that can benefit the world, especially patients,” Regev wrote in an internal email to Broad staff on Monday that was shared with STAT. “I have realized that the blend of deep biology, sophisticated computation, and new ways to marry the two — should now complete its arc with patient biology and therapies.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
